Effects of seaprose on sputum biochemical components in chronic bronchitic patients
a double-blind study vs placebo.
May 08, 1993 - Italy - Seaprose is a semialkaline proteinase endowed with proteolytic effect and antiinflammatory activity tested in different clinical trials. There is clinical evidence that seaprose reduces sputum viscoelastic properties in chronic hypersecretory bronchitis. The present study evaluated (in a double-blind design vs. placebo) the activity of seaprose on bronchial inflammation, mucus glycoprotein secretion and bronchial humoral defence mechanism in chronic bronchitic patients clinically stable (10 per group). Markers of bronchial inflammation (albumin, albumin/total protein ratio) and bronchial infection (DNA), of mucus glycoproteins (fucose and N-acetylneuraminic acid) and of humoral defence mechanism (secretory-IgA) were tested in sputum. We found that ten-day treatment with seaprose (90 mg/day) reduced sputum albumin during the observation period, the difference being statistically significant at the 18th day. The sputum albumin/total protein ratio also decreased by 50% at the end of the study. In the same group, sputum DNA, secretory-IgA, fucose and N-acetylneuraminic acid remained unchanged after treatment. The placebo group did not show any significant changes in the sputum marker substances. This study provides experimental evidence for the antiinflammatory activity of seaprose on bronchial mucosa in chronic bronchitic patients studied in a stable phase of their disease. Furthermore the drug does not seem to affect mucus glycoprotein secretion or secretory-IgA production.
Seaprose has the ability to reduce bronchial inflammation: After 10 days of treatment with Seaprose-S, chronic bronchitis patients' mucus showed reduced levels of albumin and a decrease in the albumin/total protein ratio, both accepted markers of bronchial inflammation and infection.
Moretti M, Bertoli E, Bulgarelli S, Testoni C, Guffanti EE, Marchioni CF, Braga PC.
Istituto di Tisiologia e Malattie dell' Apparato Respiratorio, Universita di Modena, Italy.
"Effects of seaprose on sputum biochemical components in chronic bronchitis patients"
Source: International Journal of Clinical Pharmacology Research (Geneva)
The statements on this Web site have not been evaluated by the Food and Drug Administration (FDA). And are not intended to diagnose, treat, cure or prevent disease. The information presented is not intended to replace medical advice or treatment from your own doctor or healthcare provider. Nothing presented here is intended as a substitute for prescription medication or any other medical treatment prescribed by your doctor.